ETC-1002: A future option for lipid disorders?

Atherosclerosis

Volumn 237, Issue 2, 2014, Pages 705-710

  Nikolic, Dragana ^a   Mikhailidis, Dimitri P ^b   Davidson, Michael H ^c   Rizzo, Manfredi ^a,e   Banach, Maciej ^d  

^a UNIVERSITY OF PALERMO   (Italy)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^c UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^d UNIVERSITY OF LODZ   (Poland)

^e Euro Mediterranean Institute of Science and Technology   (Italy)

Author keywords

Cardiometabolic risk; ETC 1002; Lipid lowering therapy; Low density lipoprotein cholesterol

Indexed keywords

ADENOSINE TRIPHOSPHATE CITRATE LYASE; ANTILIPEMIC AGENT; APOLIPOPROTEIN B; DICARBOXYLIC ACID DERIVATIVE; ETC 1002; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; LONG CHAIN FATTY ACID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; UNCLASSIFIED DRUG;

ADD ON THERAPY; ANIMAL EXPERIMENT; BLOOD PRESSURE; BODY WEIGHT; CARDIOMETABOLIC RISK; CHOLESTEROL SYNTHESIS; CLINICAL STUDY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; FATTY ACID OXIDATION; FATTY ACID SYNTHESIS; HUMAN; HYPERCHOLESTEROLEMIA; LIPOPROTEIN BLOOD LEVEL; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW;

EID: 84910066978     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2014.10.099     Document Type: Review

References (24)

1. Ballantyne C.M., Davidson M.H., Macdougall D.E., et al. Efficacy and safety of a novel dual modulator of adenosine triphosphate-citrate lyase and adenosine monophosphate-activated protein kinase in patients with hypercholesterolemia: results of a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial. J.Am. Coll. Cardiol. 2013, 62:1154-1162.
2. Esperion Therapeutics Presents Full Results of Phase 2 Clinical Study Demonstrating that ETC-1002 Lowered LDL-C by an Average of 32 Percent and Was Well Tolerated in Patients with Hypercholesterolemia and History of Statin Intolerance 2013, Available from:. http://investor.esperion.com/releasedetail.cfm?ReleaseID=807947.
3. Esperion Therapeutics, Inc., Available from:. http://www.esperion.com/therapies-progress/clinical-studies/.
4. Dragan S., Serban M.C., Banach M. Proprotein convertase subtilisin/kexin 9 inhibitors: an emerging lipid-lowering therapy?. J.Cardiovasc. Pharmacol. Ther. 2014, 10.1177/1074248414539562.
5. Banach M., Serban C., Aronow W.S., et al. Lipid, blood pressure and kidney update 2013. Int. Urol. Nephrol. 2014, 46:947-961.
6. Rizzo M., Barylski M., Rizvi A.A., Montalto G., Mikhailidis D.P., Banach M. Combined dyslipidemia: should the focus be LDL cholesterol or atherogenic dyslipidemia?. Curr. Pharm. Des. 2013, 19:3858-3868.
7. Rizzo M., Banach M., Montalto G., Mikhailidis D.P. Lipid-lowering therapies and achievement of LDL-cholesterol targets. Arch. Med. Sci. 2012, 8:598-600.
8. Esperion Therapeutics, Inc. 2014. Available from:. http://files.shareholder.com/downloads/AMDA-1UZG66/0x0x744443/0A0F2E62-8FAD-443C-B531-0F768179B9F7/ESPR_Annual_Report_2014_040214_FINAL__FINAL.PDF.
9. Understanding Key Pathways. Available from:. http://www.esperion.com/our-pathways-approach/understanding-key-pathways/.
10. Pinkosky S.L., Filippov S., Srivastava R.A., et al. AMP-activated protein kinase and ATP-citrate lyase are two distinct molecular targets for ETC-1002, a novel small molecule regulator of lipid and carbohydrate metabolism. J.Lipid Res. 2013, 54:134-151.
11. MacDougall D.E., DiCarlo L.A., Milad M.A., Vanderlngt J.T., Newton R.S. ETC-1002 was safe, well-tolerated, and reduced LDL-C in a phase I multiple-dose study of subjects with mild dyslipidemia. Atherosclerosis, Thrombosis, and Vascular Biology Scientific Sessions; April 28-30; Chicago, IL 2011.
12. Single Radiolabeled Dose Study to Investigate the Absorption, Metabolism and Excretion of [14C]-etc-1002 (NCT02044627). Available from:. https://clinicaltrials.gov/ct2/show/study/NCT02044627?term=%2522ETC-1002%2522&rank=6.
13. Goldberg R. Targeting low-density lipoprotein and dysmetabolism in type 2 diabetes mellitus. Arterioscler. Thromb. Vasc. Biol. 2014, 34:477-478.
14. Filippov S., Pinkosky S.L., Lister R.J., et al. ETC-1002 regulates immune response, leukocyte homing, and adipose tissue inflammation via LKB1-dependent activation of macrophage AMPK. J.Lipid Res. 2013, 54:2095-2108.
15. A Study of the Efficacy and Safety of ETC-1002 in Subjects with Statin Intolerance (NCT01751984). Available from:. https://clinicaltrials.gov/ct2/show/study/NCT01751984?term=%2522ETC-1002%2522&rank=9.
16. -/- Mouse by a Lipid-dependent and Independent Mechanism. ATVB Scientific Session: 137, Abstract 405 2011, C.T. Cramer, R.A. Srivastava, J. Lutostanski, C.L. Bisgaier, R.S. Newton (Eds.).
17. ANovel Small Molecule, ETC-1002, Lowers Proatherogenic Lipoproteins, Reduces Adiposity, and Improves Hepatic Steatosis in a Hyperlipidemic Hamster Model. ATVB Scientific Session: 55, Abstract 97 2011, R.A. Srivastava, T.R. Hurley, A.F. Brant (Eds.).
18. ETC-1002 Reduces Circulating and Hepatic Triglyceride Content and Improves Glycemic Control in KKAy Mice. ATVB Scientific Session: 177, Abstract 554 2011, J.C. Hanselman, C.D. Bradshaw, A.F. Brant (Eds.).
19. A Multiple Ascending Dose Study of ETC-1002 in Healthy Subjects (NCT01485146). Available from:. https://clinicaltrials.gov/ct2/show/study/NCT01485146?term=%2522ETC-1002%2522&rank=7.
20. A Multiple Ascending Dose Study of ETC-1002 in Subjects with Mild Dyslipidemia (NCT01105598). Available from:. https://clinicaltrials.gov/ct2/show/NCT01105598?term=%2522ETC-1002%2522&rank=3.
21. Evaluation of ETC-1002, Ezetimibe, and the Combination in Hypercholesterolemic Patients (NCT01941836). Available from:. https://clinicaltrials.gov/ct2/show/NCT01941836?term=%2522ETC-1002%2522&rank=5.
22. Gutierrez M.J., Rosenberg N.L., Macdougall D.E., et al. Efficacy and safety of ETC-1002, a novel investigational low-density lipoprotein-cholesterol-lowering therapy for the treatment of patients with hypercholesterolemia and type 2 diabetes mellitus. Arterioscler. Thromb. Vasc. Biol. 2014, 34:676-683.
23. A Study of the Safety, Pharmacokinetic Drug Interaction and Efficacy of ETC-1002 and Atorvastatin in Subjects with Hypercholesterolemia (NCT01779453). Available from:. https://clinicaltrials.gov/ct2/show/study/NCT01779453?term=%2522ETC-1002%2522&rank=8.
24. Evaluation of ETC-1002 vs Placebo in Patients Receiving Ongoing Statin Therapy (NCT02072161). Available from:. https://clinicaltrials.gov/ct2/show/NCT02072161?term=%2522ETC-1002%2522&rank=4.